1.Alves-Rosa F, Stanganelli C, Cabrera J, van Rooijen N, Palermo MS, Isturiz MA. Treatment with liposome-encapsulated clodronate as a new strategic approach in the management of immune thrombocytopenic purpura in a mouse model. Blood. 2000 Oct 15;96(8):2834-40. PMID: 11023519.

2.Aubin E, Lemieux R, Bazin R. Absence of cytokine modulation following therapeutic infusion of intravenous immunoglobulin or anti-red blood cell antibodies in a mouse model of immune thrombocytopenic purpura. Br J Haematol. 2007 Mar;136(6):837-43. doi: 10.1111/j.1365-2141.2007.06495.x. PMID: 17341270.

3.Zhao X, Qi X, Wang C, Zhou Z, Cao H, Wu P, Li L, Lu S, Wang Z. Idiopathic thrombocytopenic purpura: pathogenesis and potential therapeutic approach. Minerva Med. 2017 Dec;108(6):502-506. doi: 10.23736/S0026-4806.17.05252-1. Epub 2017 Jun 21. PMID: 28643502.

4.Wei H, Ding X, Ren J, Liu K, Tan P, Li D, Ma RZ. A murine model for human immune thrombocytopenic purpura and comparative analysis of multiple gene expression in bone marrow and spleen. J Genet Genomics. 2008 Nov;35(11):665-71. doi: 10.1016/S1673-8527(08)60088-0. PMID: 19022200.

5.Hansen RJ, Balthasar JP. Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia. J Pharm Sci. 2003 Jun;92(6):1206-15. doi: 10.1002/jps.10364. PMID: 12761810.

给上4和5

• 4.pdf(441.39k)


• 5.pdf(143.15k)